Recruiting PHASE3 INTERVENTIONAL 1-arm NCT06822790

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10)

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

Sponsor: Arrowhead Pharmaceuticals

Conditions Hypertriglyceridemia

Interventions Plozasiran Injection

Updated 4 times since 2025 Last updated: Dec 5, 2025 Started: Apr 9, 2025 Primary completion: Jul 31, 2028 Completion: Jul 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypertriglyceridemia, this trial is actively recruiting participants. The trial is conducted by Arrowhead Pharmaceuticals and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE3
Nov 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Mar 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arrowhead Pharmaceuticals

Data source: Arrowhead Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annapolis, United States , Asheboro, United States , Bakersfield, United States , Beavercreek, United States , Beverly Hills, United States , Bountiful, United States , Canoga Park, United States , Chicoutimi, Canada , El Paso, United States , Flint, United States and 28 more locations